Answer to "comment on fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis"
- PMID: 36239090
- DOI: 10.1111/1756-185X.14458
Answer to "comment on fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis"
Comment on
-
Comment on fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis.Int J Rheum Dis. 2023 Jan;26(1):172-174. doi: 10.1111/1756-185X.14460. Epub 2022 Oct 14. Int J Rheum Dis. 2023. PMID: 36239091 No abstract available.
References
REFERENCES
-
- Bertani L, Mumolo MG, Tapete G, et al. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol. 2020;32(9):1091-1098. doi:10.1097/MEG.0000000000001731
-
- Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 2012;47(4):435-444. doi:10.3109/00365521.2011.648953
-
- Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72(3):414-417. doi:10.1136/annrheumdis-2012-202135
-
- Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73(6):1186-1189. doi:10.1136/annrheumdis-2013-203854
-
- Mielants H, Veys EM, De Vos M, et al. The evolution of spondyloarthropathies in relation to gut histology. i clinical aaspects. J Rheumatol. 1995;22(12):2266-2272.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
